Results 81 to 90 of about 169,996 (318)

Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium

Clinical pharmacology and therapy, 2020
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in this response, but account for only a small proportion of variability in
S. Verma, T. Bergmeijer, L. Gong, J. Reny, J. Lewis, B. Mitchell, D. Alexopoulos, D. Aradi, R. Altman, K. Bliden, Y. Bradford, G. Campo, Kiyuk Chang, J. Cleator, J. Dery, N. Dridi, I. Férnandez-Cadenas, P. Fontana, M. Gawaz, T. Geisler, G. Gensini, B. Giusti, P. Gurbel, W. Hochholzer, L. Holmvang, Eun-Young Kim, Ho-Sook Kim, R. Marcucci, J. Montaner, J. Backman, R. Pakyz, D. Roden, E. Schaeffeler, M. Schwab, Jae-Gook Shin, J. Siller-Matula, J. T. ten Berg, D. Trenk, M. Valgimigli, John M. Wallace, M. Wen, M. Kubo, M. Lee, R. Whaley, S. Winter, T. Klein, A. Shuldiner, M. Ritchie   +47 more
semanticscholar   +1 more source

Clopidogrel-Atorvastatin Interaction [PDF]

Circulation, 2004
To the Editor: Clopidogrel is a pro-drug, which must be converted to its active form to exert its antiplatelet effect. This conversion appears to occur via the cytochrome P4503A4 isoenzyme.1 Several statins are substrates for CYP3A4, whereas others are not.
Mohammad J. Tafreshi, Ryan A. Hobbs
openaire   +3 more sources

Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial

British medical journal, 2019
Objective To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack ...
Yilong Wang, Weiqi Chen, Yi Lin, Xia Meng, Guohua Chen, Zhimin Wang, Jialing Wu, Dali Wang, Jianhua Li, Yibin Cao, Yuming Xu, Guohua Zhang, Xiaobo Li, Yuesong Pan, Hao Li, Xingquan Zhao, Liping Liu, Jinxi Lin, K. Dong, J. Jing, S. C. Johnston, David Wang, Yongjun Wang   +22 more
semanticscholar   +1 more source

Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik, Ainhoa Gomez‐Lumbreras, Guilherme Del Fiol, Kensaku Kawamoto, Katy E. Trinkley, Thomas Reese, Aubrey Jones, Daniel C. Malone   +7 more
wiley   +1 more source

Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study

CPT: Pharmacometrics & Systems Pharmacology
Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers (PMs) of CYP2C19 exhibit diminished antiplatelet effects.
Yun Seob Jung, Byung Hak Jin, Min Soo Park, Choon Ok Kim, Dongwoo Chae   +4 more
doaj   +1 more source

Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel

Stroke and Vascular Neurology
Background Antiplatelet agents reduce recurrence after cerebral ischaemia but are not effective in all patients, in part because of treatment resistance. The primary aim was to assess the proportion of patients who are insensitive to clopidogrel.
Philip M Bath, Nikola Sprigg, Jason Philip Appleton, Carla Richardson, Natalia Dovlatova, Jane May, Stan Heptinstall   +6 more
doaj   +1 more source

The Phenomenon of Clopidogrel High On-Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive Review

International Journal of Molecular Sciences, 2020
Clopidogrel is increasingly being used for the secondary prevention of ischemic stroke according to the updated guidelines on acute stroke management. Failure to achieve a drug response is referred to as clopidogrel resistance.
A. Wiśniewski, K. Filipska
semanticscholar   +1 more source

Risk of neutropenia with clopidogrel

Journal of the American College of Cardiology, 2000
Dr. Berger et al. presented a cogent comparison of ticlopidine and clopidogrel after intracoronary artery stent placement [(1)][1]. However, they present misleading information regarding the side effects of clopidogrel.
openaire   +3 more sources

Grapefruit juice and clopidogrel [PDF]

Canadian Medical Association Journal, 2013
Friesen[1][1] has provided thoughtful comments about the “loss of efficacy” of clopidogrel from grapefruit interactions that was reported in our article.[2][2] Because clopidogrel is commonly prescribed in Canada and is used to prevent common and serious thrombotic-mediated cardiovascular ...
openaire   +3 more sources

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

Clinical Pharmacology &Therapeutics, EarlyView.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan, Lynn Miller, Sam Wade, Jenni Ilomäki, Dickson Lukose, Jia Rong, Geoffrey I. Webb   +6 more
wiley   +1 more source